| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
In this research, we performed exploratory studies of MDSC (myeloid-derived suppressor cells) in patients with head and neck cancer. MDSC in PBMC (peripheral blood mononuclear cells) fraction increased significantly in patients with head and neck squamous cell carcinoma (HNSCC) than that in healthy control. When CD15(+) MDSC was depleted from PBMC fraction, T-cell activation was enhanced. The proportion of MDSC in PBMC was negatively correlated with the proportion of lymphocytes in white blood cells. Especially, the negative correlation was found between the proportion of MDSC in PBMC and the proportion of T-cell in PBMC. Therefore it is suggested that MDSC suppress antitumor immunity by accumulation in patients with head and neck cancer and by decreasing T-cell number and suppressing T-cell activation. Development of therapies targeted to MDSC is thought to be a possible new strategy to activate antitumor immunity in patients with head and neck cancer.
|
